Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients With Staphylococcus Aureus Bloodstream Infections (Bacteremia) Including Endocarditis
Conditions
Interventions
CF-301
Placebo
Locations
78
United States
CF-301-102 Study Site
Birmingham, Alabama, United States
CF-301-102 Study Site
Sacramento, California, United States
CF301-102 Study Site
Sylmar, California, United States
CF-301-102 Study Site
New Haven, Connecticut, United States
CF-301-102 Study Site
Newark, Delaware, United States
CF-301-102 Study Site
Atlanta, Georgia, United States
Start Date
May 23, 2017
Primary Completion Date
March 7, 2019
Completion Date
March 7, 2019
Last Updated
October 8, 2021
NCT06650501
NCT06574399
NCT06336824
NCT06695832
NCT05184764
NCT03761953
Lead Sponsor
ContraFect
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions